Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.34B |
| Revenue (ttm) | 62.40M |
| Net Income (ttm) | -342.50M |
| Shares Out | 395.16M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | 15.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,020,832 |
| Average Volume | 872,633 |
| Open | 5.93 |
| Previous Close | 5.91 |
| Day's Range | 5.65 - 5.93 |
| 52-Week Range | 3.03 - 7.07 |
| Beta | 0.78 |
| RSI | 54.39 |
| Earnings Date | Apr 29, 2026 |
About Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Thera... [Read more]
Financial Performance
In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.
Financial StatementsNews
Egetis Therapeutics AB Transcript: Leerink Global Healthcare Conference 2026
Emcitate achieved EU approval and is under FDA review, with a broad clinical dataset supporting its use in MCT8 deficiency. US launch preparations include expanded infrastructure and pricing analogs suggest a ~$1M annual price. Indication expansion and new IP strengthen the rare disease pipeline.
Egetis Therapeutics AB Transcript: Fireside chat
The CEO shared insights on rare disease drug development, highlighting progress in diagnosis, regulatory milestones, and commercialization strategies. Emcitate's approval in Europe and pending U.S. launch mark significant achievements, with further pipeline expansion and profitability expected within a year of U.S. entry.
Egetis Therapeutics AB Earnings Call Transcript: Q4 2025
Emcitate revenue grew 40% year-over-year to SEK 62.4 million, driven by EU launch and expanded access. U.S. NDA submission completed, with FDA decision expected in September 2026 and launch preparations underway. Patient identification in the U.S. surpassed 140, with further growth anticipated.
Egetis Therapeutics AB Earnings Call Transcript: Q3 2025
FDA Breakthrough Therapy designation and positive ReTRIEVE study results support Triac's NDA submission for MCT8 deficiency, with U.S. launch preparations underway. Revenue and cash position improved year-over-year, bolstered by a SEK 172 million rights issue.
Egetis Therapeutics AB Transcript: Study Result
The ReTRIACt study in MCT8 deficiency showed a significant difference in serum T3 changes between placebo and tiratricol, supporting a robust NDA submission. Regulatory milestones are on track, with a rolling submission planned for December 2025 and FDA review expected to complete in Q3 2026.
Egetis Therapeutics AB Transcript: Stifel 2025 Healthcare Conference
Emcitate, recently approved in Europe for MCT8 deficiency, is advancing toward a US rolling NDA submission, supported by robust clinical and survival data. Early access programs and commercial launches are expanding globally, with future plans for indication expansion into RTH beta.
Egetis Therapeutics AB Transcript: FDA Announcement
FDA granted rolling NDA review for MCT8, with submission starting December 2025 and review completion expected Q3 2026. The NDA is based on robust clinical data from six sources, and the retried study is now complementary. Ongoing FDA collaboration and legislative updates may impact review timelines.
Egetis Therapeutics AB Earnings Call Transcript: Q2 2025
FDA breakthrough therapy designation and Emcitate's commercial launch in Germany mark a pivotal shift to commercialization, with strong early patient conversion and expanding global partnerships. H1 revenues grew year-over-year, but guidance remains withheld due to ongoing EU pricing processes.
Egetis Therapeutics AB Earnings Call Transcript: Q1 2025
Full EU approval and imminent German launch of Emcitate mark a major commercial milestone, with U.S. NDA submission planned for 2025 and global expansion underway. Q1 revenues rose to SEK 12.7 million, and cash position improved to SEK 273 million.
Egetis Therapeutics AB Transcript: Study Update
MCT8 deficiency is a rare, severe disorder with high childhood mortality, but Triac treatment normalizes T3, improves metabolic symptoms, and may reduce mortality by threefold. Neurodevelopmental outcomes remain unchanged, but overall patient well-being improves, and future research may explore prenatal therapy and screening.
Egetis Therapeutics AB Earnings Call Transcript: Q4 2024
Full European approval of Emcitate marks a shift to commercial stage, with Germany launch set for Q2 2025 and U.S. NDA filing planned for 2025. Revenue declined year-over-year due to prior one-time income, but cash position improved after a major share issue.
Egetis Therapeutics AB Earnings Call Transcript: Q3 2024
Key milestones achieved include progress on EU approval for Emcitate, strong survival data, and a $30M share issue. Q3 revenue declined due to order timing, but cash position improved. EMA and U.S. regulatory processes remain on track.
Egetis Therapeutics AB Transcript: Study Result
Triac Trial II in young children with MCT8 deficiency showed no statistically significant improvement in neurocognitive endpoints versus historical controls, but confirmed significant T3 reduction and a strong safety profile. Regulatory timelines and approval probability remain unchanged.